Synthetic PPARα agonists have been shown to provide beneficial effects in AD mouse models by acting on APP processing and Aβ metabolism [14, 15], autophagy and lysosomal pathway [16–18], lipid peroxidation [19], and neuroinflammation [20, 21]. This evidence concerns the gene APP and Alzheimer disease.